BENZODIAZEPINE DRUGS MARKET ANALYSIS

Benzodiazepine Drugs Market, By Product (Long Acting Benzodiazepines (Chlordiazepoxide, Diazepam, Lorazepam, Alprazolam, Clonazepam, Others) and Short Acting Benzodiazepines), By Route of Administration (Oral, Injectables, Others), By Application (Anxiety Disorders, Nervousness, Sedation, Seizures, Alcohol Withdrawal, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : May 2024
Code : CMI5001
Pages :208
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

On January 5, 2024, Theravance Biopharma, Inc., a pharmaceutical company, announced results from the Phase 4 PIFR-2 study of YUPELRI (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI delivered via standard jet nebulizer compared to Spiriva (tiotropium) delivered via a dry powder inhaler (Spiriva HandiHaler) in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR).
In November 2023, Lupin, a pharmaceutical company, announced the launch of Vilfuro-G, the world's first fixed-dose triple combination drug (FDC) for the treatment of chronic obstructive pulmonary disease (COPD) in India. Vilfuro-G is available in a single-strength fixed dose, with a recommended once-daily dosage for the treatment of COPD, which refers to a group of diseases that cause airflow blockage and breathing-related problems.
In June 2022, Verona Pharma, a pharmaceutical company, announced the completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.
In January 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, launched Diazepam Injection, USP, through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 5mg/mL in 2mL dose.